Navigation Links
Helix BioPharma closes $16.9 million private placement of common shares
Date:12/19/2007

AURORA, ON, Dec. 19 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today announced the closing of its previously announced private placement, for gross proceeds of CDN$16,867,200.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains forward-looking statements regarding a proposed private placement and the Company's activities, which statements can be identified by the words "will", "anticipates", and "developing". Actual results or events could differ materially from these forward-looking statements due to numerous factors, including without limitation, the risk that the proposed placement may not close as anticipated or at all, research & development risks, Helix's need for additional future capital, the risk of unanticipated expenses, and possible changes in business strategy or plans. These and other risks and uncertainties are contained in Helix's latest Annual Information Form at http://www.sedar.com. Forward-looking statements and information are based on the assumptions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation, except as required by law, to update any forward-looking statement or information should those assumptions or expectations, or other circumstances change.
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...acy endpoint has been met for patients with advanc..., QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - A...he "Company"), a global biopharmaceutical company ...nnounced positive efficacy data from a Phase 2 stu...AEZS-108 (formerly AN-152), in patients with advan...
(Date:11/24/2009)... 24, 2009 Arena Pharmace...hat the company is scheduled to present at the Pip...ecember 1, 2009 at 11:30 a.m. Eastern Time (8:30 a...New York City. Jack Lief, Arena,s President and Ch...overview of the company, including its clinical de...
(Date:11/24/2009)...am Connects Customers with Partners Validated to P...tek Products , Ottawa, ON...ding provider of products for biological sample co...ounced its new global partner program. The program... partner community and is designed to help partner...
(Date:11/23/2009)...9 In a provocative new study, a University of Uta...sions the major cause of global warming cannot b...or society builds the equivalent of one new nuclea...at there will be any substantial near-term departu...ioxide emission rates," says the new paper by Tim ...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4
...6 Zounds Hearing, a unique manufacturing,and reta...th state-of-the-art,fidelity, price point and prof...sistive listening devices (ALDs) in an effort to a...s are now available in all of the Zounds Hearing,C...8. And, from November 26,2008, through December 7...
... 26 Ceregene, Inc., a biopharmaceutical,company, ...controlled Phase 2,trial of CERE-120 in 58 patient...d not demonstrate an appreciable difference betwee...he control group. Both groups showed an approximat...ary endpoint (Unified,Parkinson,s Disease Rating S...
...Nov. 26 Covaris Incorporated today,announced that... the shipment,of its 500th instrument unit and con...o accommodate this rapid business growth, Covaris ...nization as well as implementing a,50% expansion o...was built upon the proprietary and patented AFA(TM...
Other Biology Technology:Zounds Offers the Gift of Hearing This Holiday Season With a Range of New Products 2Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease 2Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease 3Covaris Installed Instrument Base Reaches 500 Units 2
(Date:11/25/2009)...Kent State University assistant professors recentl...ation (NSF) to continue research beneficial to und... $890,000. , Christopher Blackwood, assistant pr...was awarded grants to support two separate researc...ing Litter Decomposer Communities and Functions fr...
(Date:11/24/2009)...Lupus Research Institute (LRI) today named 12 new ....6 million, recognize innovative work across a bro...or their creativity, novelty, and potential to dri...at, and cure the complex disease of systemic lupus...ed lupus researchers across the nation and include...
(Date:11/24/2009)...ts that keep weakened and flabby arteries from col...months, those stents are no longer needed -- once ...sary. Previously, doctors had no choice but to lea...l Aviv University,s Department of Biomedical Engin...atform that carries drugs where they,re needed, th...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A coating for life 2Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 1Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 1Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 3Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 4Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 1Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 2
...uman immunodeficiency virus (HIV-1) molecular mach...functionally-specialized layers, according to a st...ia San Diego (UCSD) Antiviral Research Center (AVR...ology. , The unprecedented genetic diversity an... efforts to eradicate the global HIV/AIDS epidemic...
...uld More Than Double its Current Revenue, Stream...care Industry, SAN JOSE, Calif., Nov. 2 Titanium...ing biometric and security,solutions provider, ann...tent to acquire China Medical Systems (OTC: CHSY),...ching, developing and marketing of specialized,sof...
...d streams in remote parts of the UK, southern Scan...singly stained brown by dissolved organic matter. ...rnational team, led by researchers from UCL (Unive...tection Agency (EPA), demonstrates that the colour...l, pre-industrial state following a decline in the...
Other Biology News:Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 2Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 3Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 4Don't judge a brook by its color -- brown waters are more natural 2
...Adept CE 4100 high pressure dual piston pumps, eac...nts. The ground breaking WaveQuest UV/Visible ult...ity. The WaveQuest provides a trustworthy altern... superior stability . Hence only one detector is ...
...ples may be carried out using this high pressure s...System control and data processing is provided by ...legant, powerful and very easy to use software ope... supplied detector is the ground breaking WaveQues...
Oligonucleotides from Thermo Scientific
Pyrex brand low actinic narrow mouth Erlenmeyer flask, Pyrex ST 27 stopper from Sigma-Aldrich
Biology Products: